Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2017, Pages

  Shah, Sachin S ^a   Ohlsson, Arne ^b   Halliday, Henry L ^c   Shah, Vibhuti S ^b  

^a Surya Hospital for Women and Children   (India)

^b UNIVERSITY OF TORONTO   (Canada)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; ELASTASE; PLACEBO; ANTIINFLAMMATORY AGENT; BECLOMETASONE; DEXAMETHASONE; RESPIRATORY TRACT AGENT; STEROID;

ASSISTED VENTILATION; ASTHMA; ATTRIBUTABLE RISK; ATTRITION BIAS; BODY FLUID; CEREBRAL PALSY; CHILD BEHAVIOR CHECKLIST; DATA EXTRACTION; DETECTION BIAS; DIASTOLIC BLOOD PRESSURE; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GENERAL CONCEPTUAL ABILITY SCORE; GESTATIONAL AGE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LUNG DYSPLASIA; LUNG HEMORRHAGE; MORTALITY; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN MORTALITY; OUTCOME ASSESSMENT; OXYGEN THERAPY; PARAMETERS; PATENT DUCTUS ARTERIOSUS; PERFORMANCE BIAS; PHYSICAL DISABILITY; PNEUMOTHORAX; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPORTING BIAS; RETROLENTAL FIBROPLASIA; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SELECTION BIAS; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; SYSTOLIC BLOOD PRESSURE; TRACHEAL ASPIRATE FLUID; TREATMENT DURATION; VERY LOW BIRTH WEIGHT; WEIGHTED MEAN DIFFERENCE; ARTIFICIAL VENTILATION; CHRONIC DISEASE; INFANT; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; PREMATURITY;

ADMINISTRATION, INHALATION; ANTI-INFLAMMATORY AGENTS; BECLOMETHASONE; BRONCHOPULMONARY DYSPLASIA; BUDESONIDE; CHRONIC DISEASE; DEXAMETHASONE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; RESPIRATORY SYSTEM AGENTS; STEROIDS;

EID: 85031405838     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002058.pub3     Document Type: Review

References (67)

1. Groneck P, Goetze-Speer B, Speer CP. Effects of inhaled beclomethasone compared to systemic dexamethasone on lung inflammation in preterm infants at risk of chronic lung disease. Pediatric Pulmonology 1999;27(6):383-7. [PUBMED: 10380089]2928622
2. Halliday HL, Patterson CC, Halahakoon CWNL, European Multicenter Steroid Study Group. A multicentre, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide. Pediatrics 2001;107(2):232-40. 2928624
3. Wilson TT. Long term neurodevelopmental and psychosocial outcomes following premature birth: Has postnatal corticosteroid treatment been an over-looked factor? [PhD Thesis]. School of Psychology, Faculty of Science & Agriculture. The Queen's University of Belfast, 2005. 6863528
4. Wilson TT, Waters L, Patterson CC, McCusker CG, Rooney NM, Marlow N, et al. Neurodevelopmental and respiratory follow-up results at 7 Years for children from the United Kingdom and Ireland enrolled in a randomized trial of early and late postnatal corticosteroid treatment, systemic and inhaled (the Open Study of Early Corticosteroid Treatment). Pediatrics 2006;117(6):2196-205. [DOI: 10.1542/peds.2005-2194; PUBMED: 16740865]6863527
5. Dimitriou G, Greenough A, Giffin FJ, Kavadia V. Inhaled versus systemic steroids in chronic oxygen dependency of preterm infants. European Journal of Pediatrics 1997;156(1):51-5. [PUBMED: 9007492]2928626
6. Kovács L, Davis GM, Faucher D, Papageorgiou A. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatrica 1998;87(7):792-8. [PUBMED: 9722255]2928628
7. Mazulov O, Yablon O, Bertsun K, Vzhetson E. Corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates - are they useful?. European Respiratory Journal 2013;42(Suppl 57):5126. [erj.ersjournals.com/content/erj/42/Suppl_57/P2057.full.pdf]6863530
8. Parikh NA, Locke RG, Chidekel A, Leef KH, Emberger J, Paul DA, et al. Effect of inhaled corticosteroid on markers of pulmonary inflammation and lung maturation in preterm infants with evolving chronic lung disease. Journal of the American Osteopathic Association 2004;104(3):114-20. [PUBMED: 15083986]2928630
9. Aghajafari F, Murphy K, Willan A, Ohlsson A, Amankwah K, Mathews S, et al. Multiple courses of antenatal corticosteroids: a systematic review and meta-analysis. American Journal of Obstetetrics and Gynecology 2001;185(5):1073-80. [DOI: 10.1067/mob.2001.117635; PUBMED: 11717636]
10. Arias-Camison JM, Lau J, Cole CH, Frantz ID 3rd. Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatric Pulmonology 1999;28(3):167-74. [PUBMED: 10495332]
11. Arnon S, Grigg J, Nikander K, Silverman M. Delivery of micronised budesonide suspension by metered dose inhaler and jet nebuliser into a neonatal ventilator circuit. Pediatric Pulmonology 1992;13(3):172-5. [DOI: 10.1002/ppul.1950130309]
12. Bahadue FL, Soll R. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD001456.pub2]
13. Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau PH, Carnielli V, et al. NEUROSIS Trial Group. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. New England Journal of Medicine 2015;373(16):1497-506. [DOI: 10.1056/NEJMoa1501917; PUBMED: 26465983]
14. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Necrotising enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery 1978;187(1):1-7. [PUBMED: 413500]
15. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Archives of Disease in Childhood 1998;79(1):26-33. [DOI: 9797621]
16. Clyman RI, Mauray F, Roman C, Rudolf AM, Heymann MA. Glucocorticoids alter the sensitivity of the lamb ductus arteriosus to prostaglandin E2. Journal of Pediatrics 1981;98(1):126-8. [PUBMED: 7452389]
17. Clyman RI. Ductus arteriosus: current theories of prenatal and postnatal regulation. Seminars in Perinatology 1987;11(1):67-71.
18. Davis PG, Henderson-Smart DJ. Intravenous dexamethasone for extubation of newborn infants. Cochrane Database of Systematic Reviews 2001, Issue 4. [DOI: 10.1002/14651858.CD000308]
19. Doyle LW, Ehrenkranz RA, Halliday HL. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD001145.pub3]
20. Doyle LW, Ehrenkranz RA, Halliday HL. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews 2014, Issue 5. [DOI: 10.1002/14651858.CD001146.pub4]
21. Garland JS, Alex CP, Pauly TH, Whitehead VL, Brand J, Winston JF, et al. A three day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomised trial. Pediatrics 1999;104(1):91-9.
22. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 23 February 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015.
23. Grigg J, Arnon S, Jones T, Clarke A, Silverman M. Delivery of therapeutic aerosols to intubated babies. Archives of Disease in Childhood 1992;67(1 Spec No):25-30. [PUBMED: 1536581]
24. Groneck P, Goetze-Speer B, Opperman M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high risk preterm neonates. Pediatrics 1994;93(5):712-8. [PUBMED: 8165067]
25. Gupta GK, Cole CH, Abbasi S, Demissie S, Njinimbam C, Nielsen HC, et al. Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. Pediatric Pulmonology 2000;30(4):275-81. [PUBMED: 11015126]
26. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biology of the Neonate 1999;76(Suppl 1):29-40. [DOI: 47044; PUBMED: 10393391]
27. Halliday HL. Guidelines on neonatal steroids. Prenatal and Neonatal Medicine 2001;6(6):371-3.
28. Heyman E, Ohlsson A, Shennan AT, Heilbut M, Coceani F. Closure of patent ductus arteriosus after treatment with dexamethasone. Acta Paediatrica Scandinavica 1990;79(6-7):698-700. [PUBMED: 2386065]
29. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
30. Horbar JD, Wright EC, Onstad L, National Institute of Child Health and Human Development Neonatal Research Network. Decreasing mortality associated with introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics 1993;92(2):191-6. [PUBMED: 7710456]
31. Ibrahim H, Sinha IP, Subhedar NV. Corticosteroids for treating hypotension in preterm infants. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD003662.pub4]
32. The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Archives of Ophthalmology 1984;102(8):1130-4. [PUBMED: 6547831]
33. Jefferies AL. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Journal of Paediatrics and Child Health 2012;17(10):573-4. [PUBMED: 24294068]
34. Kotecha S, Wangoo A, Silverman M, Shaw RJ. Increase in the concentrations of transforming growth factor beta-1 in bronchoalveolar lavage fluid before development of chronic lung disease of prematurity. Journal of Pediatrics 1996;128(4):464-9. [PUBMED: 8618178]
35. Lee SK, McMillan DD, Ohlsson A, Pendray M, Synnes A, Whyte R, et al. Variations in practice and outcomes in the Canadian NICU Network: 1996-1997. Pediatrics 2000;106(5):1070-9. [PUBMED: 11061777]
36. Ng PC. The effectiveness and side effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Archives of Disease in Childhood 1993;68(3 Spec No):330-6. [PUBMED: 8466274]
37. O'Callaghan C, Hardy J, Stammers J, Stephensen T, Hull D. Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model. Archives of Disese in Childhood 1992;67(1 Spec No):20-4. [PUBMED: 1307678]
38. Onland W, Offringa M, van Kaam A. Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews 2017, Issue 8. [DOI: 10.1002/14651858.CD002311.pub4]
39. Onland W, De Jaegere AP, Offringa M, van Kaam A. Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD010941.pub2]
40. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weight less than 1500 gm. Journal of Pediatrics 1978;92(4):529-34. [PUBMED: 305471]
41. Pierce MR, Bancalari E. The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatric Pulmonology 1995;19(6):371-8. [PUBMED: 7567218]
42. Nordic Cochrane Centre. The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre. The Cochrane Collaboration, 2014.
43. Roberts D, Brown J, Medley N, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2017, Issue 3. [DOI: 10.1002/14651858.CD004454.pub3]
44. Saarela T, Vaarala A, Lanning P, Koivisto M. Incidence, ultrasonic patterns and resolution of nephrocalcinosis in very low birth weight infants. Acta Paediatrica 1999;88(6):655-60. [PUBMED: 10419252]
45. Schwartz RM, Luby AM, Scanlon JW, Kellog RJ. Effects of surfactant on morbidity, mortality and resource use in newborn infants weighing 500 to 1500 g. New England Journal of Medicine 1994;330(21):1476-80. [DOI: 10.1056/NEJM199405263302102; PUBMED: 8164699]
46. Schünemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE Working Group. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. gdt.gradepro.org/app/handbook/handbook.html. accessed prior to 12 September 2017.
47. Shah V, Ohlsson A. Postnatal dexamethasone in the prevention of chronic lung disease. Recent Advances in Paediatrics 2001;19:77-96.
48. Shah VS, Ohlsson A, Halliday HL, Dunn M. Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD001969.pub4]
49. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews 2017, Issue 10. [DOI: 10.1002/14651858.CD002057.pub4]
50. Shaw NJ, Gill AB, Weindling AM, Cooke RW. The changing incidence of chronic lung disease. Health Trends 1993;25(2):50-3. [PUBMED: 10130806]
51. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blaazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Archives of Disease in Childhood. Fetal and Neonatal Edition 2000;83(3):F177-81. [PUBMED: 11040164]
52. Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D. Inhaled corticosteroids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics 2016;138(6):e20162511. [DOI: 10.1542/peds.2016-2511; PUBMED: 27940717]
53. Sinkin RA, Cox C, Phelps DL. Predicting risk for bronchopulmonary dysplasia: selection criteria for clinical trials. Pediatrics 1990;86(5):728-36. [PUBMED: 2235227]
54. Soll RF, The Vermont Oxford Network Steroid Study Group. Early dexamethasone therapy for the prevention of chronic lung disease. Pediatric Research 1999;45:226A. [DOI: 10.1203/00006450-199904020-01345]
55. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/14651858.CD001149]
56. Speer CP, Ruess D, Harms K, Herting E, Gefeller O. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993;91(4):794-9. [PUBMED: 8464669]
57. Stark AR, Carlo WA, Tyson JE, Papile LA, Wright LL, Shankaran EF, et al. National Institute of Child Health and Human Development Neonatal Research Network. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. New England Journal of Medicine 2001;344(2):95-101. [DOI: 10.1056/NEJM200101113440203; PUBMED: 11150359]
58. Ward M, Sinn J. Steroid therapy for meconium aspiration syndrome in newborn infants. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD003485; PUBMED: 14583981]
59. Watterberg KL, Carmichael DF, Gerdes JS, Werner S, Backstorm C, Murphy S. Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. Journal of Pediatrics 1994;125(2):264-9. [PUBMED: 7913723]
60. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97(2):210-5. [PUBMED: 8584379]
61. Watterberg KL, American Academy of Pediatrics. Committee of Fetus and Newborn. Policy statement - postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Pediatrics 2012;126(4):800-8. [DOI: 10.1542/peds.2010-1534; PUBMED: 20819899]
62. Watts CL, Fanaroff AA, Bruce MC. Elevation of fibronectin levels in lung secretions of infants with respiratory distress syndrome and development of bronchopulmonary dysplasia. Journal of Pediatrics 1992;120(4 Pt 1):614-20. [PUBMED: 1552403]
63. Yeh TF, Lin YJ, Hsieh WS, Lin HC, Lin CH, Chen JY, et al. Early postnatal dexamethasone therapy for prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicentre clinical trial. Pediatrics 1997;100(4):e3.
64. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow up study. Pediatrics 1998;101(5):E7.
65. Zubrow AB, Hulman S, Kushner H, Falkner B, Philadelphia Neonatal Blood Pressure Study Group. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Journal of Perinatology 1995;15(6):470-9. [PUBMED: 8648456]
66. Shah SS, Ohlsson A, Halliday H, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2003, Issue 1. [DOI: 10.1002/14651858.CD002058]
67. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD002058.pub2]